Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 March 2001Website:
http://www.seagen.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/ADividend
Analysts recommendations
Institutional Ownership
Included in screeners
Similar companies
SGEN Latest News
Seagen (SGEN) and Astellas Pharma announce that the FDA has accepted the label expansion-seeking application for the Padcev/Keytruda combo under priority review to treat first-line bladder cancer.
Seagen reported mixed third quarter earnings, with revenue outperforming expectations on strong product sales growth as earnings fell short of estimates. The cancer-focused biotechnology company which is being acquired by Pfizer reported revenue of $649 million for 3Q.
Biotech stock Seagen Inc (NASDAQ:SGEN) scored an all-time high of $215.04 today, building on a Friday breakout from a consolidation between $204 and $210.
Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.
Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.
Seagen said on Wednesday its breast cancer therapy in combination with Roche's Kadcyla helped extend the time patients lived without their disease progressing in a late-stage trial.
Seagen (NASDAQ: SGEN ) stock is slipping on Tuesday after one of the company's directors sold some of their shares. According to a filing with the Securities and Exchange Commission (SEC), Seagen director Daniel Welch sold 1,864 shares of SGEN stock.
Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago.
The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.
Clay Siegall, the Seagen founder who resigned last year following an arrest and allegations of domestic violence, is jumping back into the biotech world as CEO and president of Morphimmune.
What type of business is Seagen?
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
What sector is Seagen in?
Seagen is in the Healthcare sector
What industry is Seagen in?
Seagen is in the Biotechnology industry
What country is Seagen from?
Seagen is headquartered in United States
When did Seagen go public?
Seagen initial public offering (IPO) was on 09 March 2001
What is Seagen website?
https://www.seagen.com
Is Seagen in the S&P 500?
No, Seagen is not included in the S&P 500 index
Is Seagen in the NASDAQ 100?
No, Seagen is not included in the NASDAQ 100 index
Is Seagen in the Dow Jones?
No, Seagen is not included in the Dow Jones index
When does Seagen report earnings?
Next earnings report date is not announced yet